

Ryuya Yamanaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8589754/publications.pdf>

Version: 2024-02-01

111
papers

3,045
citations

172207

29
h-index

189595

50
g-index

112
all docs

112
docs citations

112
times ranked

3559
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. PLoS ONE, 2021, 16, e0251272.	1.1	7
2	miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. PLoS ONE, 2020, 15, e0229577.	1.1	16
3	Metabolome analysis reveals excessive glycolysis via PI3K/AKT/mTOR and RAS/MAPK signaling in methotrexate-resistant primary CNS lymphoma-derived cells. Clinical Cancer Research, 2020, 26, clincanres.3851.2018.	3.2	14
4	GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. Scientific Reports, 2020, 10, 8435.	1.6	9
5	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Scientific Reports, 2019, 9, 10004.	1.6	24
6	Promising Prognosis Marker Candidates on the Status of Epithelial-Mesenchymal Transition and Glioma Stem Cells in Glioblastoma. Cells, 2019, 8, 1312.	1.8	23
7	Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells. BMC Cancer, 2019, 19, 910.	1.1	7
8	CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme. PLoS ONE, 2019, 14, e0216825.	1.1	17
9	Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells. International Journal of Clinical Oncology, 2019, 24, 1020-1029.	1.0	7
10	MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. PLoS ONE, 2019, 14, e0210400.	1.1	23
11	Trilateral retinoblastoma: A systematic review of 211 cases. Neurosurgical Review, 2019, 42, 39-48.	1.2	21
12	Concerns and Returns to Work in Patients with Breast Cancer Receiving Outpatient Chemotherapy: a Pilot Study. Asia-Pacific Journal of Oncology Nursing, 2019, 6, 187-192.	0.7	2
13	Frequency and risk factors for subsyndromal delirium in an intensive care unit. Intensive and Critical Care Nursing, 2018, 47, 15-22.	1.4	23
14	Radiation-induced gliomas: a comprehensive review and meta-analysis. Neurosurgical Review, 2018, 41, 719-731.	1.2	60
15	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. Oncotarget, 2018, 9, 27471-27486.	0.8	30
16	The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2018, 58, 95-101.	0.3	43
17	Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. Oncotarget, 2018, 9, 19065-19078.	0.8	37
18	Secondary glioma following acute lymphocytic leukemia: therapeutic implications. Neurosurgical Review, 2017, 40, 549-557.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Late relapse of primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 475-477.	0.6	8
20	Secondary Craniofacial Sarcomas Following Retinoblastoma: A Systematic Review. <i>World Neurosurgery</i> , 2017, 101, 722-730.e4.	0.7	7
21	Radiation-Induced Schwannomas and Neurofibromas: A Systematic Review. <i>World Neurosurgery</i> , 2017, 104, 713-722.	0.7	13
22	Radiation-Induced Malignant Peripheral Nerve Sheath Tumors: A Systematic Review. <i>World Neurosurgery</i> , 2017, 105, 961-970.e8.	0.7	38
23	Effects and safety of mechanical bathing as a complementary therapy for terminal stage cancer patients from the physiological and psychological perspective: a pilot study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1066-1072.	0.6	7
24	Long-term survivors of primary central nervous system lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 101-107.	0.6	5
25	Radiation-Induced Sarcomas of the Central Nervous System: A Systematic Review. <i>World Neurosurgery</i> , 2017, 98, 818-828.e7.	0.7	19
26	Radiation-Induced Meningiomas: An Exhaustive Review of the Literature. <i>World Neurosurgery</i> , 2017, 97, 635-644.e8.	0.7	75
27	Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review. <i>Cancers</i> , 2017, 9, 103.	1.7	35
28	Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 21-25.	0.3	25
29	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. , 2017, 37, 5655-5666.		26
30	Prognostic significance of S-phase fractions in peritumoral invading zone analyzed by laser scanning cytometry in patients with high-grade glioma: A preliminary study. <i>Oncology Letters</i> , 2016, 11, 2106-2110.	0.8	1
31	Whole-Genome Sequencing of Primary Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4112-4112.	0.6	2
32	Radiation-Induced Glioma. , 2015, , .		2
33	Assessment of autonomic nervous system function in nursing students using an autonomic reflex orthostatic test by heart rate spectral analysis. <i>Biomedical Reports</i> , 2015, 3, 831-834.	0.9	10
34	Thr160 of Axin1 is critical for the formation and function of the β -catenin destruction complex. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 411-415.	1.0	5
35	Gene Expression Signature-Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma. <i>Annals of Oncology</i> , 2014, 25, v58.	0.6	0
36	Experiences and Expectations for Glioma Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2014, 4, 355.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature. <i>Journal of Neuro-Oncology</i> , 2014, 117, 261-268.	1.4	12
38	Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. <i>Cancer Science</i> , 2013, 104, 1285-1294.	1.7	39
39	Gene expression signature-based prognostic risk score in patients with glioblastoma. <i>Cancer Science</i> , 2013, 104, 1205-1210.	1.7	56
40	Primary Central Nervous System Lymphoma ~ Recent Advance on Clinical Research. , 2013, , .		1
41	Radiation-Induced Glioblastoma Following Radiotherapy for Pituitary Adenomas: Marked Response to Chemotherapy. <i>Journal of Neurology & Neurophysiology</i> , 2013, 04, .	0.1	6
42	Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. <i>International Journal of Oncology</i> , 2012, 40, 721-30.	1.4	6
43	Gene Expression Signature-Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 5672-5681.	3.2	35
44	Dendritic Cell Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 187-200.	0.8	13
45	M2 Macrophage/Microglial Cells Induce Activation of Stat3 in Primary Central Nervous System Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 93-99.	0.3	64
46	Characteristics of patients with brain metastases from lung cancer in a palliative care center. <i>Supportive Care in Cancer</i> , 2011, 19, 467-473.	1.0	26
47	Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. <i>Cancer Biology and Therapy</i> , 2010, 10, 1266-1279.	1.5	46
48	Management of refractory or relapsed primary central nervous system lymphoma (Review). <i>Molecular Medicine Reports</i> , 2009, 02, 879-85.	1.1	7
49	Molecularly targeted therapies for glioma. <i>Annals of Neurology</i> , 2009, 66, 717-729.	2.8	22
50	Dendritic-cell- and peptide-based vaccination strategies for glioma. <i>Neurosurgical Review</i> , 2009, 32, 265-273.	1.2	38
51	Medical management of brain metastases from lung cancer (Review). <i>Oncology Reports</i> , 2009, 22, 1269-76.	1.2	54
52	Immunotherapeutic Approach for Glioma by Alphaviruses as Positive Strand RNA Viruses. , 2009, , 125-140.		0
53	Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen ^{A2} glioma patients. <i>Cancer Science</i> , 2008, 99, 1656-1662.	1.7	14
54	Cell- and peptide-based immunotherapeutic approaches for glioma. <i>Trends in Molecular Medicine</i> , 2008, 14, 228-235.	3.5	64

#	ARTICLE	IF	CITATIONS
55	Results of Treatment of 112 Cases of Primary CNS Lymphoma. Japanese Journal of Clinical Oncology, 2008, 38, 373-380.	0.6	23
56	EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Molecular Cancer Therapeutics, 2008, 7, 2768-2778.	1.9	119
57	Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system. Journal of Neurosurgery, 2008, 109, 536-546.	0.9	11
58	Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncology Reports, 2008, , .	1.2	2
59	Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncology Reports, 2008, 19, 1277-83.	1.2	13
60	Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: A preliminary study. Leukemia and Lymphoma, 2007, 48, 1429-1433.	0.6	6
61	Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leukemia and Lymphoma, 2007, 48, 1119-1126.	0.6	13
62	Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma. A preliminary report. Leukemia and Lymphoma, 2007, 48, 1019-1022.	0.6	9
63	Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncology Reports, 2007, , .	1.2	5
64	Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opinion on Biological Therapy, 2007, 7, 645-649.	1.4	15
65	Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncology Reports, 2007, 17, 629-36.	1.2	14
66	Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncology Reports, 2006, 15, 1569.	1.2	20
67	Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. Oncology Reports, 2006, 16, 1093.	1.2	27
68	Increased expression of CCAAT/enhancer binding protein β correlates with prognosis in glioma patients. Oncology Reports, 2006, 15, 595.	1.2	18
69	Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene, 2006, 25, 5994-6002.	2.6	101
70	277. Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial. Molecular Therapy, 2006, 13, S106.	3.7	0
71	Novel immunotherapeutic approaches to glioma. Current Opinion in Molecular Therapeutics, 2006, 8, 46-51.	2.8	10
72	Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. Annals of Hematology, 2005, 84, 447-455.	0.8	15

#	ARTICLE	IF	CITATIONS
73	Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 107-113.	1.4	34
74	Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma. <i>Clinical Cancer Research</i> , 2005, 11, 5900-5911.	3.2	130
75	Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines. <i>International Journal of Oncology</i> , 2005, 27, 1231.	1.4	11
76	Induction of Antigen-Specific Immune Responses Against Malignant Brain Tumors by Intramuscular Injection of Sindbis DNA Encoding Gp100 and IL-18. <i>DNA and Cell Biology</i> , 2005, 24, 317-324.	0.9	32
77	Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial. <i>Clinical Cancer Research</i> , 2005, 11, 4160-4167.	3.2	301
78	Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines. <i>International Journal of Oncology</i> , 2005, 27, 1231-9.	1.4	7
79	Alphavirus vectors for cancer gene therapy (Review). <i>International Journal of Oncology</i> , 2004, 24, 919.	1.4	7
80	Development of Improved Sindbis Virus-Based DNA Expression Vector. <i>DNA and Cell Biology</i> , 2004, 23, 75-80.	0.9	15
81	Gene therapy of brain tumor with endostatin. <i>Drugs of Today</i> , 2004, 40, 931.	2.4	6
82	Advances for the treatment of primary central nervous system lymphoma (review). <i>Oncology Reports</i> , 2004, 12, 563-8.	1.2	6
83	Tumor mRNA loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 632-637.	2.0	54
84	Immunohistochemical analysis of myelination following hemicranial irradiation in neonatal rats. <i>Neuroscience Letters</i> , 2003, 353, 131-134.	1.0	7
85	CCAAT/enhancer binding proteins are expressed in the gerbil hippocampus after transient forebrain ischemia. <i>Neuroscience Letters</i> , 2003, 337, 106-110.	1.0	10
86	Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. <i>British Journal of Cancer</i> , 2003, 89, 1172-1179.	2.9	251
87	Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. <i>Journal of Neurosurgery</i> , 2003, 99, 746-753.	0.9	52
88	Dendritic cell-based glioma immunotherapy (Review). <i>International Journal of Oncology</i> , 2003, 23, 5.	1.4	12
89	Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. <i>International Journal of Oncology</i> , 2003, 23, 913.	1.4	0
90	Dendritic cell-based glioma immunotherapy (review). <i>International Journal of Oncology</i> , 2003, 23, 5-15.	1.4	48

#	ARTICLE	IF	CITATIONS
91	Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. <i>International Journal of Oncology</i> , 2003, 23, 913-23.	1.4	1
92	Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. <i>Journal of Neurosurgery</i> , 2002, 97, 611-618.	0.9	50
93	Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus-mediated tumor complementary DNA. <i>Journal of Neurosurgery</i> , 2002, 97, 1184-1190.	0.9	23
94	Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. <i>Cancer Gene Therapy</i> , 2001, 8, 796-802.	2.2	60
95	Ostip2, a Novel Oncoprotein that Associates with the Rho Exchange Factor Ost. <i>DNA and Cell Biology</i> , 2001, 20, 383-390.	0.9	1
96	Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus-mediated complementary DNA. <i>Journal of Neurosurgery</i> , 2001, 94, 474-481.	0.9	63
97	Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. <i>Neurosurgical Focus</i> , 2000, 9, 1-6.	1.0	25
98	Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. <i>Journal of Neuro-Oncology</i> , 1999, 43, 27-34.	1.4	23
99	A Novel Human CCAAT/Enhancer Binding Protein Gene, C/EBP μ , Is Expressed in Cells of Lymphoid and Myeloid Lineages and Is Localized on Chromosome 14q11.2 Close to the T-Cell Receptor α/β Locus. <i>Genomics</i> , 1996, 35, 30-38.	1.3	111
100	Antisense DNA Approach to the Growth of Human Glioma Cells. , 1996, , 441-447.		0
101	Growth inhibition of human glioma cells modulated by retrovirus gene transfection with antisense IL-8. <i>Journal of Neuro-Oncology</i> , 1995, 25, 59-65.	1.4	29
102	Cytokine gene expression on glioma cell lines and specimens. <i>Journal of Neuro-Oncology</i> , 1994, 21, 243-247.	1.4	29
103	Immunohistochemical Analysis of Tumor-infiltrating Lymphocytes and Adhesion Molecules (ICAM-1, Tj ETQq1 1 0.784314 rgBT /Over	1.0	7
104	Immunological analysis of the rats with anterior hypothalamic lesions. <i>Journal of Neuroimmunology</i> , 1993, 48, 45-52.	1.1	10
105	Effects of ACNU and Cranial Irradiation on the Mouse Immune System. <i>Neurologia Medico-Chirurgica</i> , 1993, 33, 65-70.	1.0	6
106	Effects of Irradiation on Cytokine Production in Glioma Cell Lines. <i>Neurologia Medico-Chirurgica</i> , 1993, 33, 744-748.	1.0	27
107	Effects of Irradiation on the Expression of the Adhesion Molecules (NCAM, ICAM-1) by Glioma Cell Lines. <i>Neurologia Medico-Chirurgica</i> , 1993, 33, 749-752.	1.0	5
108	Comparison of Stereotactic Aspiration, Craniotomy, and Conservative Treatment for Putaminal Hemorrhage. <i>Neurologia Medico-Chirurgica</i> , 1988, 28, 986-990.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Changes in Cerebral Hemodynamics after Extracranial-intracranial Bypass. Neurologia Medico-Chirurgica, 1988, 28, 981-985.	1.0	3
110	Medical Management of Brain Metastases from Lung Cancer. , 0, , .		4
111	Advances for the treatment of primary central nervous system lymphoma (review). Oncology Reports, 0, , .	1.2	1